Edesa Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Edesa Biotech
EDSA Stock  USD 1.12  0.03  2.75%   
Edesa Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Edesa Biotech's valuation are provided below:
Gross Profit
311.2 K
Market Capitalization
9.3 M
Enterprise Value Revenue
128.5 K
Revenue
500
Earnings Share
(1.27)
We have found one hundred twenty available fundamental signals for Edesa Biotech, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Edesa Biotech prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 886.1 M. The current year's Enterprise Value is expected to grow to about 872 M

Edesa Biotech Total Revenue

0.0

Check Edesa Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edesa Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.3 K, Interest Expense of 993.4 K or Selling General Administrative of 3.7 M, as well as many indicators such as Price To Sales Ratio of 2.7 K, Dividend Yield of 0.0 or PTB Ratio of 115. Edesa financial statements analysis is a perfect complement when working with Edesa Biotech Valuation or Volatility modules.
  
Build AI portfolio with Edesa Stock
Check out the analysis of Edesa Biotech Correlation against competitors.
For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

Edesa Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets8.8 M15.6 M9.5 M
Slightly volatile
Total Current Liabilities1.3 M1.2 M1.3 M
Very volatile
Cash13 M12.4 M6.6 M
Slightly volatile
Non Current Assets Total1.3 M2.3 M1.3 M
Slightly volatile
Cash And Short Term Investments6.8 M12.4 M7.3 M
Pretty Stable
Common Stock Shares Outstanding6.9 M6.5 M1.9 M
Slightly volatile
Liabilities And Stockholders Equity8.8 M15.7 M9.5 M
Slightly volatile
Other Current Assets85 K89.5 K290.1 K
Slightly volatile
Other Stockholder Equity17.8 M17 M8.1 M
Slightly volatile
Total Liabilities2.2 M1.4 M2.3 M
Pretty Stable
Total Current Assets7.6 M13.2 M8.1 M
Pretty Stable
Net Receivables518.9 K739.3 K515.7 K
Slightly volatile
Intangible Assets1.5 M2.3 M1.9 M
Slightly volatile
Accounts Payable2.2 M2.1 M1 M
Slightly volatile
Common Stock Total Equity27 M16.7 M25.5 M
Pretty Stable
Common Stock42 M62.7 M36.9 M
Slightly volatile
Short Term Investments3.9 M7 M4.3 M
Slightly volatile
Property Plant Equipment26.6 K28 K224.8 K
Slightly volatile
Long Term Investments48 K41.8 K54.6 K
Slightly volatile
Net Invested Capital2.7 M2.9 M6.8 M
Slightly volatile
Capital Stock44.3 M73.3 M49.2 M
Pretty Stable
Capital Surpluse262.2 K295 K322 K
Slightly volatile
Short and Long Term Debt Total17 K17.9 K113.5 K
Slightly volatile
Other Liabilities44.3 K50.2 K36.2 K
Slightly volatile
Non Current Liabilities Other76.8 K60.9 K101.2 K
Slightly volatile
Short Term Debt17 K17.9 K97.7 K
Slightly volatile

Edesa Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization127.3 K137.2 K125.3 K
Pretty Stable
Selling General Administrative3.7 M4.9 M3.5 M
Slightly volatile
Other Operating Expenses7.4 M9.1 M7.1 M
Slightly volatile
Total Operating Expenses7 M9 M6.8 M
Slightly volatile
Research Development4.2 M4.2 M4 M
Slightly volatile
Cost Of Revenue102 K107.3 K362.4 K
Slightly volatile
Interest Income2.2 K2.3 K232.2 K
Slightly volatile
Reconciled Depreciation141.3 K137.2 K147.7 K
Slightly volatile
Net Interest Income2.8 K2.9 K63.3 K
Very volatile
Selling And Marketing Expenses146.8 K165.1 K180.2 K
Slightly volatile

Edesa Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.1 M839.1 K877.2 K
Pretty Stable
Begin Period Cash Flow1.1 M1.2 M4.5 M
Very volatile
Total Cash From Financing Activities20.6 M19.6 M8.3 M
Slightly volatile
End Period Cash Flow13 M12.4 M6.6 M
Slightly volatile
Depreciation134.8 K137.2 K126.2 K
Pretty Stable
Change To Netincome2.7 M2.6 M1.1 M
Slightly volatile
Issuance Of Capital Stock21.3 M20.2 M7.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.7 K2.6 K1.2 K
Slightly volatile
PTB Ratio11511027.9976
Pretty Stable
Days Sales Outstanding92.2763.8170.6068
Very volatile
Book Value Per Share41.742.653641.9508
Pretty Stable
Average Payables1.3 M1.3 M755.1 K
Slightly volatile
Stock Based Compensation To Revenue2.022.961.3509
Slightly volatile
Capex To Depreciation1.832.031.4584
Pretty Stable
PB Ratio11511027.9976
Pretty Stable
EV To Sales2.7 K2.6 K1.1 K
Slightly volatile
Payables Turnover3.923.732.5017
Slightly volatile
Sales General And Administrative To Revenue6.196.946.8692
Slightly volatile
Research And Ddevelopement To Revenue3.745.954.8333
Slightly volatile
Capex To Revenue0.40.670.6002
Pretty Stable
Cash Per Share45.8876.911442.5792
Pretty Stable
Days Payables Outstanding96.21013 K
Pretty Stable
Income Quality0.70.50561.031
Slightly volatile
Intangibles To Total Assets0.0130.01370.2136
Pretty Stable
Net Debt To EBITDA1.451.62681.3124
Slightly volatile
Current Ratio10.599.90438.8255
Very volatile
Receivables Turnover5.625.9215.9698
Very volatile
Shareholders Equity Per Share41.742.653641.9521
Pretty Stable
Debt To Equity0.01280.01150.0185
Slightly volatile
Capex Per Share2.011.781.7678
Pretty Stable
Average Receivables100.2 K105.4 K224.4 K
Slightly volatile
Revenue Per Share2.252.373.0744
Slightly volatile
Interest Debt Per Share0.120.10050.0973
Pretty Stable
Debt To Assets0.00870.0060.0116
Slightly volatile
Price Book Value Ratio11511027.9976
Pretty Stable
Days Of Payables Outstanding96.21013 K
Pretty Stable
Ebt Per Ebit1.211.47110.9044
Slightly volatile
Company Equity Multiplier1.971.87961.3311
Slightly volatile
Long Term Debt To Capitalization0.01120.01260.0138
Slightly volatile
Total Debt To Capitalization0.01250.01140.0181
Slightly volatile
Debt Equity Ratio0.01280.01150.0185
Slightly volatile
Quick Ratio10.549.90438.7324
Very volatile
Net Income Per E B T1.11.00321.0089
Pretty Stable
Cash Ratio7.989.45155.98
Pretty Stable
Days Of Sales Outstanding92.2763.8170.6068
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.161.231.0673
Slightly volatile
Price To Book Ratio11511027.9976
Pretty Stable
Fixed Asset Turnover1.051.11.4197
Pretty Stable
Debt Ratio0.00870.0060.0116
Slightly volatile
Price Sales Ratio2.7 K2.6 K1.2 K
Slightly volatile
Asset Turnover0.02810.02960.047
Slightly volatile
Price Fair Value11511027.9976
Pretty Stable

Edesa Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap886.1 M843.9 M221.5 M
Pretty Stable
Enterprise Value872 M830.5 M216.2 M
Pretty Stable

Edesa Fundamental Market Drivers

Forward Price Earnings0.1716
Cash And Short Term Investments10.8 M

Edesa Upcoming Events

9th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of December 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

About Edesa Biotech Financial Statements

Edesa Biotech stakeholders use historical fundamental indicators, such as Edesa Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Edesa Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Edesa Biotech's assets and liabilities are reflected in the revenues and expenses on Edesa Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Edesa Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.6 K-1.7 K
Cost Of Revenue107.3 K102 K
Stock Based Compensation To Revenue 2.96  2.02 
Sales General And Administrative To Revenue 6.94  6.19 
Research And Ddevelopement To Revenue 5.95  3.74 
Capex To Revenue 0.67  0.40 
Revenue Per Share 2.37  2.25 
Ebit Per Revenue(17.67)(18.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:
How To Invest In Edesa
Details
Is Edesa Stock a good investment?
Details
What is Edesa Biotech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Edesa Biotech Correlation against competitors.
For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. Projected growth potential of Edesa fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Edesa Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.27)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.57)
Return On Equity
(1.00)
Investors evaluate Edesa Biotech using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edesa Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Edesa Biotech's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Edesa Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edesa Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edesa Biotech's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY